65,437 trials
Patients With High-risk Prostate Cancer
Primary: Number of Participants With Circulating Tumor Cells in the Peripheral Blood — 60; 5 Participants
Astigmatism Bilateral
Primary: Ease of Insertion(Handling) — 9.1; 9.2 units on a scale
Constipation · Chronic Idiopathic Constipation · CIC
Primary: % of Subjects With Treatment Emergent Adverse Events — 108 Participants
Refractory Diffuse Large B Cell Lymphoma
Primary: Phase 1: Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) — 0; 0; 1 Participants
Healthy Volunteers
Primary: Pharmacokinetics: Maximum Drug Concentration (Cmax) of LY2623091 — 61.9; 66.9; 61.8; 64.2 nanograms per milliliter (ng/mL)
Neoplasms · Cancer
Primary: Number of Participants With 1 or More Adverse Events (AEs) or Any Serious AEs — 19; 9 Participants
Hepatocellular Carcinoma
Primary: Overall Survival (OS) — 16.39; 14.69 Months — p=0.0752
Constipation
Primary: Treatment Response — 32 Participants
Wound Healing Disorder · Impaired Wound Healing · Abdominal Wound Healing Disorder
Primary: Time to Complete Wound Closure — 36.1; 39.1 Days
Acute Respiratory Infection
Primary: Fever Duration (With a Superiority Cut-off Level δ=-0,52 Days) — 2.04; 2.26 day — p=<0.05
Cataract
Primary: Monocular, Photopic Distance Corrected Intermediate Visual Acuity (DCIVA) at 66 Centimeter (cm) — 0.053; 0.370 logMAR — p=< 0.0001
Psoriasis
Primary: Change From Baseline in Psoriatic Skin Infiltrate Thickness — 0.89; 0.92; 0.97; 0.93 micrometer (μm) — p=0.9883
Refractive Error · Myopia
Primary: Least Squares Mean Distance Visual Acuity With Study Lenses — -0.13; -0.12 logMar
Hypercholesteremia
Primary: Percent Change From Baseline in LDL-C at Day 28 — -25.54 Percent Change — p=0.0041
Anesthesia, Local · Pain
Primary: Mean Pain Scores Following Injection — 3.0; 3.3 score on a scale — p=0.38